What a recent FDA warning letter does and doesn’t say
What a recent FDA warning letter does and doesn’t say
Being an exceptional compounding professional means you never stop learning
We advocate for compounding pharmacies and facilities on a range of state and federal issues affecting patient access to compounded medications. We represent pharmacists and technicians in both traditional 503A compounding pharmacies and 503B outsourcing facilities, as well as prescribers, patients, educators, and suppliers. We’re 5,000 members strong and growing.
What a recent FDA warning letter does and doesn’t say
PCF names scholarship awardees
Compounders notch 175 Capitol Hill meetings
Webinar: A clinical guide to the peptides your patients are asking about
APC sent members of FDA’s Pharmacy Compounding Advisory Committee a briefing memo on how and why traditional 503A pharmacy compounding works.
Unapproved obesity drug spawns a black market frenzy